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Following publication of the original article \[[@CR1]\], the authors reported that the chemotherapy dosages in the footnote of Table 1 should be in mg, and not mg/m^2^.

The footnote for Table 1 should read as follows:

This table describes the demographic characteristics of the patients at baseline.

^a^To compare distribution of cancer diagnosis for intervention versus control, the diagnoses with \< 10 observations are grouped together into another category (i.e., esophageal, testicular, gastrointestinal, miscellaneous, sarcoma, bladder, gastric, pancreatic and unknown primary).

^b^For participants receiving multiple neurotoxic chemotherapy agents, dose category was determined based on the highest dose of one of the specific agents they were receiving.

^c^Paclitaxel \< 700 mg; Oxaliplatin \< 800 mg; Docetaxel \< 300 mg; Cisplatin \< 300 mg.

^d^Paclitaxel 700--1400 mg; Oxaliplatin 800--1000 mg; Docetaxel 300--600 mg; Cisplatin 300--600 mg.

^e^Paclitaxel \> 1400 mg; Oxaliplatin \> 1000 mg; Docetaxel \> 600 mg; Cisplatin \> 600 mg.

^f^Neurotoxic chemotherapy dose reduction due to other symptom-related causes included fatigue, pain, skin changes, bowel problems, or breathing problems.
